Coloplast A/S (COLO-B) fair value: what the stock is really worth
As of Oct 19, 2026: fair value (intrinsic value) of Coloplast A/S stock DKK 386, price DKK 467, upside -17.4%, quality 59 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 13, 2026.
How to read this chart
60‑month range kr 372.30 – kr 1,031 · fair‑value band kr 241.19 – kr 482.19 · the kr 466.90 price screens above the kr 385.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 13, 2026.
Follow Coloplast A/S in your weekly email
Every Wednesday you see whether Coloplast A/S is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally.
Show moreShow less
The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments.
It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand.
The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation.
In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand.
Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence.
Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand.
Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Stock analysis
Coloplast A/S (COLO-B) currently trades at kr 466.90, while our model-based Fair Value estimate is kr 385.75, 17.4% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Dividend Discount group reads highest at a median of kr 427.01 per share, and 7 of the 24 models we run sit above the kr 466.90 price.
Bear case: the Earnings-Based group reads lowest at kr 126.95, and 17 of the 24 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 241.19 (bear) to kr 482.19 (bull), the price of kr 466.90 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Coloplast A/S reported revenue of 27.9B DKK in FY2025 versus 19.4B DKK in FY2021, a compound +9.4%/yr. Reported net income was 3.6B DKK in FY2025, compounding −6.8%/yr from FY2021.
Key figures
Market cap 105B DKK (≈ $15.8B) Large · P/E ratio 34.0 · P/S ratio 3.70 · EPS (TTM) kr 12.28 · Dividend yield 4.9% · Net margin 9.7% · Return on equity 18.5% · Return on assets (EBIT) 20.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 74 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 21% below its 52-week high and 25% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −39% fair-value upside, at −17%, COLO-B screens cheaper than that median.
Fair Value models
Bearkr 241.19Fair Value kr 385.75Bullkr 482.19
Price kr 466.90 · Upside -17.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+3.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+1.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.9%
Dividend (yield on the price)4.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3.9% vs 3.7%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.32% → 27%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (Denmark: IMF forecast 2.1% a year to 2030, 2.0% from 2016 to 2025) that is about +5.6% a year for the price and +2.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Pricing power in niche medical devices supports high margins and returns on equity, while sparse insider and human capital data limit the overall assessment of business quality.
Main risk: Currency or reimbursement shifts could pressure margins in the core chronic care business.
Coloplast completed the transfer of its controlling stake to a foundation on October 1 as part of generational planning. This locks in long-term stable ownership under the new CEO. Our models see the stock as overvalued. Will the structure give management room to pursue bolder expansion in areas like interventional urology or keep the focus tightly on protecting margins in core chronic care?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 184 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Above median
Fair Value upside−17.4% · Below median
Profitability
Return on equity (12 months)18.5% · Top 25%
Return on assets7.5% · Above median
Net margin (12 months)9.7% · Above median
Operating margin (12 months)26.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)5.7% · Below median
Dividend yield (12 months)4.9% · Top 25%
Balance sheet
Debt / equity1.20× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)34.0× · Pricier than median
P/B6.53× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Coloplast A/S Fair Value". https://www.fairvalue-calculator.com/stock/COLO-B
Frequently asked questions
Is Coloplast A/S (COLO-B) overvalued or undervalued?
As of Oct 13, 2026, our model estimates a fair value of kr 385.75 versus a price of kr 466.90, about −17% upside (overvalued).
What is the fair value of COLO-B?
Our model-based fair value for Coloplast A/S is kr 385.75 (as of Oct 13, 2026), built from audited fundamentals. The current price: kr 466.90.
What is the quality score of COLO-B?
Coloplast A/S has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Coloplast A/S (COLO-B)?
Our model-based price target is the fair value of kr 385.75 (as of Oct 13, 2026) from 24 valuation models. Cautious scenario kr 241.19, optimistic scenario kr 482.19. It is a calculation from audited fundamentals, not an analyst target.
What is the Coloplast A/S stock forecast for 2026?
Our models put fair value at kr 385.75, about −17% upside versus a price of kr 466.90 (overvalued). Cautious scenario kr 241.19, optimistic scenario kr 482.19. The calculation is refreshed regularly with new filings.
What is the revenue of Coloplast A/S (COLO-B)?
Coloplast A/S reported trailing-twelve-month revenue of about 28.4B DKK (latest available figure, as of Oct 13, 2026).
Does Coloplast A/S pay a dividend?
Coloplast A/S currently shows a dividend yield of 4.93% relative to its recent price (as of Oct 13, 2026).
What growth is priced into Coloplast A/S (COLO-B)?
For today's price to be fair in a discounted-cash-flow model, Coloplast A/S would have to grow free cash flow by +7.8 % per year for five years (discount rate 8.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.5 % per year. As of Oct 13, 2026.
What discount rate (WACC) does the fair value of COLO-B use?
Our models discount Coloplast A/S at 8.0 %: a base by market capitalisation (large), damped by beta 0.56, country premium for Denmark. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Coloplast A/S that is +7.8 % per year a year over ten years, using the same discount rate (8.0 %) and the same formula as our fair value.
How much growth has Coloplast A/S (COLO-B) delivered so far?
Over the past 5 years revenue at Coloplast A/S grew +8.5 % a year. The price currently implies +7.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Coloplast A/S (COLO-B) growing?
The median revenue growth in the sector is +5.6 % a year. That is the yardstick for the growth priced into Coloplast A/S (+7.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Coloplast A/S (COLO-B)?
The free-cash-flow yield on the price is 5.07 %: that much free cash flow Coloplast A/S produces per unit of market value. When it exceeds the discount rate of our models (8.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Coloplast A/S (COLO-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Coloplast A/S it is kr 385.75 per share (as of Oct 13, 2026), against a price of kr 466.90. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Coloplast A/S stock overvalued or undervalued in 2026?
As of Oct 13, 2026, COLO-B trades above its calculated fair value: price kr 466.90, fair value kr 385.75, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of COLO-B?
No. The price is what the market pays today (kr 466.90); the fair value is what the company's own numbers justify (kr 385.75). For Coloplast A/S the two are kr 81.15 per share apart. That gap is exactly why we show both numbers side by side.
How much is Coloplast A/S worth?
The market values Coloplast A/S at about 105B DKK (market capitalisation, as of Oct 13, 2026). Per share that is kr 466.90; our models calculate a fair value of kr 385.75 per share.
What do the bullish and bearish scenarios say about COLO-B?
Our models span a range for Coloplast A/S: cautious scenario kr 241.19, base kr 385.75, optimistic kr 482.19 per share (as of Oct 13, 2026, price kr 466.90). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of COLO-B?
Coloplast A/S trades at a price-to-earnings ratio of 34.0 (as of Oct 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 385.75 is built from several models across several years. Other multiples: PEG 1.1, P/B 6.5, P/S 3.7, EV/EBITDA 14.3.
What is the PEG ratio of COLO-B?
The PEG ratio of Coloplast A/S is 1.07 (P/E divided by earnings growth, as of Oct 13, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Coloplast A/S (COLO-B)?
Balance-sheet figures for Coloplast A/S (as of Oct 13, 2026): return on equity 18.5%, debt of 1.20 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is COLO-B from its 52-week high?
Coloplast A/S trades at kr 466.90, about 21% below its 52-week high of kr 588.52 and 25% above the low of kr 372.30 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of kr 385.75 is for.
Which stocks are comparable to Coloplast A/S?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Coloplast A/S stock attractive at the current price?
The data as of Oct 13, 2026: price kr 466.90, calculated fair value kr 385.75 (−17%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of COLO-B calculated?
We run Coloplast A/S through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 385.75, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Coloplast A/S itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Coloplast A/S (COLO-B)?
The closing price on Oct 19, 2026 was kr 466.90. Our model-based fair value is kr 385.75, about −17% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Coloplast A/S right now?
Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 241.19 to kr 482.19) leaves room in how you read the outcome.
Where does the earnings growth of Coloplast A/S (COLO-B) come from?
Earnings per share at Coloplast A/S grew +8.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +7.1 %, EBIT margin −0.5 %, tax rate −0.4 %, residual (interest, one-offs) +1.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Coloplast A/S
How large is the market capitalisation of Coloplast A/S (COLO-B)?
The market capitalisation of Coloplast A/S is 105B DKK (≈ $15.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Coloplast A/S (COLO-B)?
The price-to-sales ratio of Coloplast A/S is 3.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Coloplast A/S (COLO-B)?
Earnings per share at Coloplast A/S are kr 12.28 (price ÷ EPS = P/E 34.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Coloplast A/S (COLO-B)?
The dividend yield of Coloplast A/S is 4.9% (payout 187%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Coloplast A/S (COLO-B)?
The net margin of Coloplast A/S is 9.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Coloplast A/S (COLO-B)?
The return on equity (ROE) of Coloplast A/S is 18.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Coloplast A/S (COLO-B)?
On an EBIT basis the return on assets of Coloplast A/S is 20.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Coloplast A/S (COLO-B)?
The operating margin of Coloplast A/S is 26.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Coloplast A/S (COLO-B)?
Revenue at Coloplast A/S is growing +5.7% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Coloplast A/S (COLO-B)?
Earnings per share at Coloplast A/S are growing +81.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Coloplast A/S (COLO-B) carry?
The net debt of Coloplast A/S is 21.7B DKK (fiscal year 2025, ≈ 4.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Coloplast A/S in the live analysis
One click puts Coloplast A/S on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 13, 2026